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Abstract Multiple antigen peptides (MAP) have been demon-
strated to be e⁄cient immunological reagents for the induction
of immune responses to a variety of infectious agents. Several
peptide domains of the hepatitis A virus (HAV) capsid proteins,
mainly VP1 and VP3, are the immunodominant targets for a
protective antibody response. In the present study we analyse
the immunogenic properties of a tetrameric heterogeneous pal-
mitoyl-derivatised MAP containing two de¢ned HAV peptide
sequences, VP1(11^25) and VP3(102^121), in rabbits immu-
nised with either Freund’s adjuvant or multilamellar liposomes.
The immune response was evaluated with a speci¢c enzyme
immunoassay using MAP[VP1+VP3], VP1 and VP3 as targets.
The avidity of the immune response was measured by a non-
competitive enzyme-linked immunosorbent assay and by the sur-
face plasmon resonance technology. Antisera raised against the
lipo-MAP peptide entrapped in liposomes demonstrated high
avidity of binding with a⁄nity rate constants approximately
one order of magnitude greater than those obtained with the
Freund’s protocol.
5 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The practical development of modern vaccines has been
greatly advanced by the availability of synthetic antigens.
The use of such synthetic antigens might be more acceptable
for human therapy since synthetic peptides do not have any of
the potential dangers associated with the induction of an in-
fection by recombinant viruses. However, progress has been
hindered in some cases by poor immunogenicity of the anti-
gens. This handicap can be overcome by the use of potent
immunoadjuvants, though only few adjuvants used in exper-
imental models are allowed for use in man.
Multiple antigen peptides (MAP) [1], synthetic macromole-
cules containing de¢ned B and/or T cell epitopes of one or
more antigens, have been demonstrated to be e⁄cient immu-
nological reagents for the ampli¢cation in the analysis and
induction of immune responses to a variety of infectious
agents [2].
Recently, we reported the synthesis and the immunogenicity
of several peptide sequences derived from hepatitis A virus
(HAV) capsid proteins when administered to laboratory ani-
mals in di¡erent forms [3^5]. Overall, the VP3(102^121) pep-
tide sequence appeared to be more immunogenic than VP1
and VP2 peptides. The highest anti-HAV titres were also ob-
served in mice immunised with VP1 and, particularly, VP3
peptides and neutralisation of HAV infectivity was achieved.
Moreover, immune responses generated by peptides entrapped
in liposomes were of higher magnitude than those induced by
free peptides.
Besides, in a previous work we have reported investigative
results about the antigenicity of a diepitope MAP containing
the sequences HAV-VP1(11^25) and HAV-VP3(110^121). Our
results have shown that branched peptides could be very use-
ful for the development of new diagnostic tests [6^8].
Modi¢cation of the lipophilic properties of peptides has
been used in the development of an immunisation strategy.
It has been reported that the use of a covalently coupled fatty
acid moiety enhances the immunogenicity of an unmodi¢ed
peptide [9]. A hypothesis has been proposed on the a⁄nity of
lipid chains for cell membranes, targeting the peptide to the
cell surface followed by passive di¡usion across the cell mem-
brane, delivery to the cytosol and migration into the cell com-
partments [10,11]. The conventional design of MAP without a
lipophilic adjuvant attachment has been successful in many
systems to elicit high-titre antibodies in animals [12^14]. How-
ever, the advantages of a MAP with a built-in adjuvant are
quite clear. It removes the obstacle of an extraneous adjuvant
and it can be used in a macromolecular assemblage approach
containing a combination of needed peptide antigens, a non-
immunogenic core matrix as a carrier, a built-in palmitoyl
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moiety as the adjuvant and liposomes as the vehicle. All these
are required components for an e¡ective vaccine formulation.
Taking into account our previous results and since the com-
bination of adjuvant e¡ects of liposomes and a built-in lipid
anchor could replace the need for an extraneous adjuvant
such as Freund’s, which is toxic and unacceptable in humans,
we herein report the design, synthesis and immunogenic stud-
ies of a tetrameric heterogeneous MAP containing two of the
HAV peptide sequences previously described, speci¢cally
VP1(11^25) and VP3(101^121), as well as the lipid tail of
palmitic acid.
2. Materials and methods
2.1. Peptide synthesis
The synthesis of the diepitopic lipophilic MAP shown in Fig. 1 was
carried out in a 0.1 mmol scale utilising a continuous £ow £uoren-9-
ylmethoxycarbonyl (Fmoc) method [15]. A NovaSyn1 TG resin
(polyethylene glycol-linked PS) functionalised with Rink amide linker
(0.2 mmol/g) was used in a continuous £ow Milligen 9050 PepSynthe-
sizer1. The general strategy that was followed for the synthesis of the
MAP construct is summarised in Fig. 2.
Following removal of the linker Fmoc-protecting group, by contin-
uous £ow (3.50 ml/min) treatment with 20% piperidine^dimethylfor-
mamide (DMF) for 6 min, 0.3 mmol of Dde-Lys(Fmoc)-OH [16]
previously activated with 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetrameth-
yluronium tetra£uoroborate:N-hydroxybenzotriazole:N,N-diisopro-
pylethylamine (TBTU:HOBt:DIEA, 1:1:2) was coupled to the linker.
The coupling was complete in 2 h as judged by the picrylsulphonic
acid test [15].
NO-Acylation with palmitic acid was carried out by, ¢rstly, removal
of the NO-Fmoc-protecting group followed by addition of a triple
excess of palmitic acid that was activated with N,N-diisopropylcarbo-
diimide (DIPCDI) and HOBt (1:1). The reaction mixture was gently
agitated overnight and checked by the picrylsulphonic acid test for
completion of the reaction.
The NK-Dde-protecting group was then removed by treatment with
2% hydrazine in DMF [16]. Deprotection was monitored by the ab-
sorption of the resulting 3,6,6-trimethyl-4-oxo-4,5,6,7-tetrahydro-1H-
indazole at 300 nm and was completed within 10 min.
The tetravalent lysine core was obtained by sequential coupling of
0.4 mmol of Fmoc-Lys(Fmoc)-OH and 0.8 mmol of Fmoc-Lys(Dde)-
OH, which were incorporated through TBTU:HOBt:DIEA (1:1:2)-
mediated carboxyl activation.
The assembly of the peptide sequence HAV-VP1(11^25) was then
accomplished at both NK-lysine positions. Amino acid side chain pro-
tection was e¡ected by the following: trityl (triphenylmethyl) for glu-
tamine and asparagine; tert-butyl for aspartic acid, glutamic acid,
serine and threonine. An eightfold molar excess of Fmoc-amino acids,
TBTU, HOBt and DIEA (1:1:1:2) was used throughout the synthesis
in a stepwise manner. The reaction column e¥uent was subjected to
continuous UV monitoring by passage through an Ultrospec II LKB
40501 spectrophotometer at 290 nm. Typical acylation and deprotec-
tion traces were obtained indicating satisfactory progress in assembly.
Double coupling was used to introduce the asparagine residue. The
peptide assembly was terminated by N-capping with di-tert-butyl di-
carbonate.
At this point, the lysine core NO-Dde group was deprotected by
treatment with 2% hydrazine in DMF. A small amount of the peptidyl
resin was removed from the reaction column, washed with DMF,
dichloromethane and methanol, and dried in vacuo. The monoepi-
topic lipophilic MAP was concomitantly side chain-deprotected and
cleaved from the resin by treatment with a mixture of TFA in the
presence of triisopropylsilane (TIPS) and water as scavengers (TFA:
TIPS:H2O, 9.5:0.25:0.25) for 6 h with occasional agitation at room
temperature. Then, the resin was ¢ltered and washed with TFA. The
¢ltrate was evaporated in vacuo to dryness and the crude peptide was
precipitated with diethyl ether (10 ml) to a¡ord a white solid, which
was collected, dissolved in water (25 ml) and lyophilised.
Reversed-phase high-performance liquid chromatography (HPLC)
analysis was performed on a Hypersil 300 AR C18 column (4.6U150
mm). The eluents were A: H2O (0.05% TFA) and B: 90% MeCN:10%
H2O (0.05% TFA). The elution pro¢le was a linear gradient of
5^100% B in 40 min at a £ow rate of 1.20 ml/min, and a major elution
peak with a retention time of 26 min was observed.
Electrospray mass spectrometry (MS) spectra con¢rmed the ex-
pected molecular mass of the lipophilic monoepitopic MAP ([MHþ]
= 3900.2). Puri¢cation of the crude molecule was achieved by prepa-
rative HPLC on a Kromasil C-8 column. The £ow rate was 4.5 ml/
min with a gradient of 40^70% B in 20 min.
The assembly of the HAV-VP3(101^121) sequence was then per-
formed at both exposed lysine NO-amino groups of the monoepitopic
lipophilic MAP resin intermediate. During the synthesis of the VP3
sequence, the Cys residues present in the native peptide were replaced
by 2-aminobutyric acid (Abu) residues. This amino acid has the same
hydrophobic and steric properties as cysteine, but avoids the reactivity
of the Cys thiol group without modifying the immunochemical prop-
erties of the parent peptide [17]. During peptide assembly, trifunc-
tional amino acids were side chain-protected by the following:
2,2,5,7,8-pentamethyl-chroman-6-sulphonyl for arginine; trityl for
glutamine; tert-butyl for aspartic acid and serine; and tert-butoxycar-
bonyl (Boc) for tryptophan.
The two initial amino acid residues of the sequence were coupled
manually and double coupling was used for the remainder in order to
ensure e⁄ciency of the synthesis.
The ¢nal protected diepitopic peptidyl resin was collected as before,
dried in vacuo, and treated with the following cleavage mixture:
TFA:H2O:1,2-ethanedithiol:TIPS (9.25:0.25:0.25:0.25) at 25‡C for
6 h. The reaction mixture was ¢ltered, the ¢ltrate was evaporated to
dryness in vacuo and the residual peptide material was precipitated
with diethyl ether to give a white solid. The crude peptide was then
suspended in water (25 ml) and lyophilised. Electrospray MS analysis
showed the presence of the expected diepitopic lipophilic MAP
([MHþ] = 8846.55) after partial puri¢cation by ultracentrifugation in
water. The semi-puri¢ed MAP synthetic construct was also character-
ised by amino acid analysis as shown in Table 1.
2.2. Peptide entrapment in liposomes
Multilamellar vesicles (MLV liposomes) were prepared as previ-
ously described [3]. Brie£y, 40 mg of phosphatidylcholine, 20 mg
cholesterol and 3 mg of lipophilic MAP were evaporated from a chlo-
roform^methanol (2:1, v/v) solution. The samples were subjected to
the vacuum of an oil pump to eliminate the last traces of the solvents.
A 0.9% aqueous NaCl solution was added to the dry lipid peptide,
and the suspension gently stirred for 1 h at room temperature. After
preparation, the MLV liposomes were washed two times by successive
centrifugation at 25 000Ug and resuspension of the pellets in 0.9%
saline. The peptide content of liposomes was determined by quanti-
tative amino acid analysis. The analysis was carried out in a Pico-
Tag1 system (Waters, Stockport, UK). Sample was hydrolysed in 6 M
HCl at 110‡C for 24 h. Vesicle size was determined by measurement
of the sample di¡usion coe⁄cient using photon correlation spectros-
copy. The phospholipid content was determined as previously de-
scribed [18], and the characterisation of the liposomes^MAP-
[VP1+VP3] preparation is summarised in Table 2.Fig. 1. Primary structure of MAP[VP1+VP3].
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2.3. Antibody production
Anti-peptide sera were prepared by immunising two rabbits with
the free peptide and the liposome-entrapped peptide following the
inoculation protocol outlined below.
One animal (rabbit 1) was immunised subcutaneously with 200 Wg
in 1 ml of heterogeneous MAP[VP1+VP3] with an equal volume of
complete Freund’s adjuvant (Difco, Detroit, MI, USA). The second
animal (rabbit 2) was immunised with the same peptide,
MAP[VP1+VP3] anchored on liposomes without adjuvant. Animals
were boosted with four injections of 200 Wg of peptides either in
combination with incomplete Freund’s adjuvant or in MLV liposomes
at 3-week intervals.
Serum samples were obtained before each immunisation and also
1 week after inoculation. Animal care procedures complied with the
Institutional Animal Care and Use Committee Guidelines.
Polyclonal IgG were puri¢ed by protein G a⁄nity (HiTrap1 pro-
tein G, Pharmacia Biotech) according to standard procedures. One
millilitre on rabbit antiserum was adsorbed to the column in binding
bu¡er (20 mM sodium phosphate, pH 7.0); after washing, bound IgG
was eluted with 0.1 M citric acid, pH 3.5. The collected fractions were
immediately neutralised to pH 7.2 with 1 M Tris^HCl pH 9.0. Immu-
noglobulin concentrations were established by spectrophotometry.
The fractions with the highest absorbance were pooled to a¡ord 600
Wg/ml ¢nal concentrations.
2.4. Enzyme-linked immunosorbent assay (ELISA)
In order to characterise the immune reactivity of sera towards the
MAP[VP1+VP3], VP1 and VP3 peptide sequences, the synthetic pep-
tides were used as coating agents in ELISA microplates.
The synthetic peptides were diluted with coating bu¡er (0.2 M car-
bonate/bicarbonate-bu¡ered saline, pH 9.7) to a ¢nal concentration of
10 Wg/ml and 100 Wl was added to each microwell (Maxisorp, 96F,
Nunc, Roskilde, Denmark). The microtitre plates were incubated at
room temperature overnight. After washing the plates with phos-
phate-bu¡ered saline (PBS), pH 7.2, containing 0.05% Tween 20, un-
occupied binding sites were blocked with 300 Wl of PBS containing 3%
skimmed milk powder at room temperature for an additional 2 h.
Then, the plates were rinsed with washing bu¡er, dried and frozen
for later use in the detection of antibodies against MAP[VP1+VP3],
VP1 and VP3 peptides.
For non-competitive ELISA assays, on each peptide-coated micro-
well, 100 Wl of serum (diluted 1/100 with PBS containing 3% skimmed
milk powder) was incubated at room temperature overnight. The
microwells were washed three times with washing bu¡er before the
addition of 100 Wl of horseradish peroxidase-conjugated goat anti-
rabbit IgGs as detector antibodies (Dakopatts, Dako, Denmark),
and were incubated for 2 h at room temperature. After washing the
microwells three times, the colour was developed by adding 100 Wl of
the substrate (4 Wl H2O2 in 50 mM sodium phosphate^citric acid
bu¡er, pH 5.0, containing 0.4 mg/ml o-phenylenediamine dihydro-
chloride (Sigma)).
2.5. Avidity calculation
A protocol based on Beatty’s calculations was used to measure
a⁄nity in monoclonal antibodies [19]. This method is based on the
law of mass action and uses the total antibody concentration added
per well rather than the bound or free ratio. The method does not
require a⁄nity puri¢cation of the standard speci¢c antibody used by
other methods [20].
Microplates were sensitised, in the same conditions as described
above, with di¡erent MAP[VP1+VP3] concentrations (0.125, 0.062,
0.031 and 0.015 Wg/ml). Each peptide concentration was incubated
with 1/4 serial dilutions of the puri¢ed IgG corresponding to each
serum sample for 1 h at room temperature. After washing, the micro-
plates were incubated with 1/1000 horseradish peroxidase-conjugated
goat Q-chain-speci¢c anti-rabbit (Dakopatts). The assay was then de-
veloped as described above for the non-competitive ELISA.
The ELISA curves of optical density (OD) at 492 nm versus the
logarithm of concentration were sigmoid in nature. The method is
based upon the law of mass action and uses the total antibody con-
centration added per well [Ab]t. The method compares the OD-50 of
two sigmoid curves of antibody serial dilutions on plates coated with
two di¡erent antigen concentrations. The OD at any point of the
sigmoid dilution curve of OD versus the logarithm of concentration
is presumed to be a direct re£ection of the amount of antibody bound
to the antigen in the well. At 50% of OD-100, OD-50, the amount of
antibody bound to antigen in the well is half the amount of antibody
bound at OD-100. Taking into account the combination of antigen
concentration in the well and the dilution of the sera, an estimation of
the constant of a⁄nity (Ka) can be formulated as: Ka = 1/2 (2[Abt at
OD-50] minus [Abt at OD-100]).
2.6. Surface plasmon resonance (SPR) studies
To evaluate the biospeci¢c interactions between puri¢ed IgG anti-
bodies raised against the MAP[VP1+VP3] peptide, we also used bio-
sensor technology. The Biacore 1000 analytical instrument, sensor
chip CM5 and maintenance kit, the amine coupling kit containing
N-hydroxysuccinimide, N-ethyl-NP-(3-diethylaminopropyl)-carbodi-
imide, ethanolamine hydrochloride adjusted to pH 8.5 using NaOH
and the running bu¡er (HBS) containing 10 mM HEPES pH 7.4, 150
mM NaCl, 3.4 mM EDTA and 0.005% surfactant P20 were provided
by Biacore (Saint Quentin-en-Yvelines, France). CM dextran sodium
salt and sodium acetate were obtained from Fluka. All bu¡ers were
¢ltered and thoroughly degassed prior to use.
Several parameters were studied to optimise the binding method.
Di¡erent pH values and di¡erent peptide concentrations were as-
sayed. Finally, immobilisation was performed at 25‡C and at a £ow
rate of 10 Wl/min in HBS as a running bu¡er following the procedure
previously described [8]. To generate the coupled peptide injections,
dissociation bu¡er was used prior to the regeneration cycle (1 min
pulse with 100 mM NaOH). The £ow rate of the IgG samples was
constant at 10 Wl/min. Control experiments were performed using
sensor chips activated according to the protocol described but without
peptide coupled.
Prior to using the IgG solutions, the diluent bu¡er (Tris^HCl, pH
9.0) was replaced by the HBS BIA bu¡er (100 mM HEPES pH 7.4,
150 mM NaCl, 3.4 mM EDTA and 0.005% v/v surfactant P20). Ex-
change was performed on a G-25 Sephadex column (NAP-5, Pharma-
cia Biotech). The IgG concentration range was quanti¢ed by spec-
trometry and used at 600 Wg/ml.
The resonance signal (absolute response in resonance units (RU))
was recorded continuously during passage of a sample and the di¡er-
ence between the optical signals measured before and after serum
injection (relative response in RU) was related to the amount of
bound antibodies anti-HAV peptides. The contact time between a
sample and the speci¢c surface was 10 min. Dissociation of bound
antisera was observed for 10 min. The same peptide surface was used
repeatedly to study all the samples. This was accomplished by washing
away the associated antibodies by an injection of 10 Wl of 100 nM
NaOH between tests. Sensor chips were stored between experiments at
4‡C in a capped test tube containing running bu¡er.
Real-time binding interactions between the MAP[VP1+VP3] pep-
tide linked to a biosensor matrix and antibodies free in solution were
recorded as RU and are displayed with respect to the time (x-axis)
along the y-axis of a sensorgram. The integrated BIAevaluation 3.1
software was employed to calculate kinetics.
Data points from the early part of the dissociation phase were ¢tted
to the manufacturer’s model equations for calculations of dissociation
rate constant (Kd, s31) for each polyclonal antiserum. Comparison of
the binding avidity of antibodies in di¡erent sera was performed by
measurement of the reciprocal (1/Kd) of the dissociation constants
[21].
3. Results
Synthesis of the macromolecular construct MAP[VP1+VP3]
was successfully accomplished using a combination of orthog-
onal Dde amino protection and Fmoc-based solid-phase
chemistry [15,16]. The overall synthetic strategy for the un-
ambiguous assembly of the diepitopic lipophilic MAP that is
based on a tetrameric lysine core is summarised in Fig. 2.
Analysis by MS was carried out during the synthesis, in which
the monoepitopic MAP intermediate was cleaved from the
polymer support and subjected to both reversed-phase
HPLC and electrospray MS analysis. For the ¢nal macromo-
lecular product, after cleavage from the polymer support, the
identity of the puri¢ed synthetic protein construct was con-
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¢rmed by electrospray MS, and a satisfactory amino acid
analysis (Table 1).
For formulation of an e¡ective immunogenic preparation,
MLV liposomes were selected in order to achieve good yields
in the MAP incorporation process. Since the MAP[VP1+VP3]
construct bears the lipid tail of the palmitoyl moiety, it was
incorporated into the lipid mixture from the beginning of the
process of liposome preparation, thus increasing the entrap-
ment e⁄ciency. The MAP[VP1+VP3] peptide/phospholipid
ratio shown in Table 2 was high enough to carry out the
inoculation protocol in a similar way as for the non-entrapped
immunogen.
Both rabbits immunised with the synthetic MAP[VP1+VP3]
peptide mounted a high antibody response. The antibody titre
increased signi¢cantly after the second immunisation and
reached a plateau after the third injection (Fig. 3A,B). Fur-
thermore, antibody titres 1 month after the last immunisation
were observed to decrease in rabbit 1. In contrast, the sera of
rabbit 2 immunised using the liposome formulation continued
to display strong antibody titres detectable at 1/100 dilution
up to 3 months (data not shown). Furthermore, the speci¢city
of the response was con¢rmed by competitive ELISA: only
the MAP peptide, up to nanomolar concentrations, was able
to inhibit the enzyme immunoassay.
Immune sera recognised the inoculating peptide
MAP[VP1+VP3] in both animals, but only animal 2 recog-
nised independently both linear peptide components of
MAP[VP1+VP3], these being the VP1(11^25) and VP3(102^
121) peptide sequences, at high titres after the third immuni-
sation. The animal immunised with Freund’s adjuvant dis-
played a slight and transient response to VP1 peptide but
no response to VP3 peptide (Fig. 3).
In order to analyse whether the immune responses mounted
in rabbits were equivalent to those in humans we performed a
competitive assay, as previously described [7], using an anti-
human absorbed anti-IgG horseradish peroxidase not reacting
with rabbit as second antibody. Rabbit antibodies were able
to compete with the human antiserum, con¢rming that the
synthetic peptide could mimic the B cell epitopes of native
proteins (data not shown). We have previously described
that the peptide formulations used in this study were recog-
nised by the immune sera from patients su¡ering an acute
hepatitis A infection [7].
To compare the a⁄nity of antibodies induced by both im-
munisation protocols, we performed studies with both biosen-
sor and enzyme immunoassay methods. Protein G a⁄nity-
puri¢ed IgG was obtained from each serum sample, and the
test was standardised for the same concentration of 600 Wg/ml.
We decided not to use peptide a⁄nity-puri¢ed antibodies in
order to not discriminate antibodies with higher a⁄nity dis-
playing non-realistic results. We assume that following protein
A a⁄nity puri¢cation, di¡erences in peptide binding could be
attributed to di¡erences in avidity of total IgG.
Using Beatty’s approach, the Ka for rabbit 1, immunised
Table 1
MAP characterisation by amino acid analysis
Asx (Asp+Asn) 7.3 (8)
Thr 3.3 (4)
Ser 2.5 (4)
Glx (Glu+Gln) 9.3 (10)
Pro 4.1 (4)
Gly 4.2 (4)
Ala 2.0 (2)
Val 11.1 (10)
Met 0.4 (2)
Ile 4.1 (4)
Leu 3.6 (4)
Phe 7.7 (8)
Lys 4.5 (4)
Arg 1.7 (2)
Trp n.d.
Theoretical values are in parentheses. Trp was not determined, and
Ser, Thr and Met are known to undergo some degradation during
6 M HCl hydrolytic treatment.
Table 2
Vesicle size and peptide and phospholipid of MAP-liposome conju-
gate
Size (nm) 2370
Polydispersity 0.97
Phospholipid content (mg/ml) 7.7
Peptide content (mg/ml) 0.7
Peptide (mg)/phospholipid (mg) 0.09
Fig. 2. Strategy of solid-phase peptide synthesis (SPPS) of
MAP[VP1+VP3].
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with Freund’s adjuvant protocol, ranged between 2.88 and
7.30U106 M31. The calculated Ka for rabbit 2, immunised
with MAP entrapped liposomes, was 4.56U106 to 2.90U107
M31 (Table 3). Furthermore, the sera from this animal dis-
played an increase in antibody avidity tested with the immu-
nogen MAP[VP1+VP3], probably re£ecting the additive e¡ect
of speci¢c antibodies mounted against VP1 and VP3 besides
antibodies recognising the conformational epitope of
MAP[VP1+VP3]. Thus, the a⁄nity constant, calculated by
the ELISA, was up to one order of magnitude greater in
the sera of the rabbit immunised with MAP entrapped in
liposomes than in the rabbit immunised with the same peptide
with the classical Freund’s adjuvant protocol. Fig. 4 shows an
experimental ELISA curve for puri¢ed IgG at di¡erent
MAP[VP1+VP3] coating concentrations.
For the biosensor technology, we chose the strategy of
binding the peptide MAP[VP1+VP3] to the chip and utilising
the polyclonal IgG as analyte to avoid variability on the coat-
ing IgG to the chip.
Kinetic analysis entailed data of a single £ow cell after
subtraction of the background sensorgram readings. Using
the BIAevaluation 3.0.2 software (Biosensor AB), we pro-
ceeded to ¢t data results to three di¡erent models predeter-
mined in the BIAevaluation software. The Langmuir model is
the simplest model for 1:1 interaction between an analyte
(IgG) and immobilised ligand (MAP peptide). The bivalent
analyte model assumes that a bivalent analyte (IgG) can
Fig. 3. Time course and IgG responses obtained in rabbits after im-
munisation with MAP[VP1+VP3]. Immunisations are indicated by
the arrows and antibody speci¢city of bleedings is indicated as fol-
lows: rhombs MAP[VP1+VP3], triangles VP1 and squares VP3 in
rabbits immunised with complete Freund’s adjuvant (A) and MLV
(B).
Fig. 4. Experimental enzyme immunoassay curve for puri¢ed IgG at
di¡erent MAP[VP1+VP3] coating concentrations. The concentra-
tions of MAP[VP1+VP3] in the coating solution were: 0.125, 0.063,
0.031 and 0.015 Wg/ml. The calculated antibody concentrations at
OD-50 were respectively: 3.276, 4.992, 8.580 and 11.700 Wg/ml.
Table 3
Kinetic analysis of puri¢ed IgG with MAP[VP1+VP3] using SPR and ELISA
Weeks SPR ELISA
400 Wg/ml 200 Wg/ml
RU Kd (s31) 1/Kd (s) RU Kd (s31) 1/Kd (s) Ka (M31)
Rabbit 1
3 920 5.81U1034 1 720 580 5.26U1034 1 900 2.88X1.23U106
6 295 5.07U1034 1 970 180 4.31U1034 2 320 7.30X0.33U106
9 250 4.58U1034 2 180 200 4.03U1034 2 480 7.05X0.43U106
12 220 4.95U1034 2 020 105 4.95U1034 2 020 4.01X0.78U106
Rabbit 2
3 695 6.28U1034 1 590 470 6.65U1034 1 500 4.56X0.75U106
6 382 2.38U1034 4 200 215 2.22U1034 4 500 4.76X1.85U106
9 350 7.06U1035 14 200 260 1.98U1034 5 050 5.11X1.89U106
12 702 3.81U1036 262 000 480 ^ ^ 2.90X0.68U107
Rabbit 1 was immunised with Freund’s adjuvant and rabbit 2 with a liposome formulation. The dissociation rate constants (Kd) from SPR
were obtained from the resulting sensorgrams of two di¡erent IgG concentrations, 400 Wg/ml and 200 Wg/ml. The reciprocal dissociation rate
constant (1/Kd) was also calculated. ELISA results show the avidity constant obtained by means of equations based on the law of mass action.
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bind to one or two ligands or sites in one complexed MAP.
The heterogeneous ligand-parallel reaction describes an inter-
action between one analyte and two independent ligands. This
model was selected considering the heterogeneous immobilisa-
tion of ligand (amine coupling, the ligand has multiple attach-
ment points) and the nature of the MAP peptide [VP1 and
VP3]. In this model, the binding curve obtained is simply the
sum of the two independent reactions.
For good ¢tting to ideal data, M2 may be of the same order
of magnitude as the noise in RU; typically less than 2, but in
practice, values less than 10 are acceptable. As shown in Table
4, the M2 values of our experimental data do not ¢t any of the
three models. Furthermore, linear transformation of the bind-
ing data showed non-linear plots, indicating that the binding
follows complex models (data not shown).
Another parameter useful to estimate the a⁄nity is the
calculation of the association (Ka) and dissociation (Kd) con-
stants. The dissociation rate analysis calculates the amount of
antibody per second dissociated after reaching the steady state
(Fig. 5) and seems to be more discriminative than the Ka
[21,22].
Two di¡erent IgG concentrations (400 Wg/ml and 200 Wg/
ml) were used in order to ensure that measurements were
made at the saturation concentration of antibody, conditions
in which this kinetic parameter is independent of the IgG
concentration. At either concentration, the MAP[VP1+VP3]
peptides in liposomes elicit antisera with highest avidity, mea-
sured by a reciprocal rate constant (1/Kd) of 262 000 which
were up to two orders of magnitude greater than observed
with the avidity antisera elicited by immunisation with
Freund’s adjuvant, 1/Kd of 2020 (Table 3).
4. Discussion
The main aim in the development of a peptide-based vac-
cine is to induce the same immunity as with the whole viral
proteins but using selected short peptide fragments containing
the most potent antigenic determinants. The methods avail-
able for the location of these antigenic determinants can be
divided into two groups, experimental and computational.
Computational methods are usually based on physicochemical
structural properties such as hydrophilicity, surface accessibil-
ity and segmental mobility. These data were considered, as
previously described, to select VP1 and VP3 peptide fragments
containing potentially active B and T cell epitopes [3,23].
Although the most widely used vehicle for vaccine delivery
in humans consists of aluminium hydroxide, other vaccine
vehicles that have shown promise are liposomes [24]. In our
studies, a liposomal formulation containing MAP[VP1+VP3]
has proved to be successful in terms of high level of mean
antibody content and low reactogenicity.
A way to overcome the loss of non-entrapped peptide dur-
ing liposome preparation can be the incorporation of hydro-
phobic anchors to the amino- or carboxy-terminal ends, which
on the basis of previous ¢ndings dramatically enhances their
immunogenicity in the absence of adjuvant [25,26]. Thus, the
regioselective NO-palmitoyl derivatisation was designed to
modify the hydrophobicity of the MAP and to favour the
incorporation into the liposome surface.
The rationale for anchoring the palmitoyl-MAP[VP1+VP3]
on liposomes was to mimic the external appearance of the
virion, particularly of the surface protein. Furthermore, the
lipid anchor serves a dual role, as a built-in adjuvant and as a
lipid-anchoring moiety [27]. At the same time the combination
of adjuvant e¡ects of liposomes and the built-in lipid anchor
may replace the need for an extraneous adjuvant such as
Freund’s, which is toxic and unacceptable for use in humans.
There is general agreement that both encapsulated and sur-
face-bound liposomal antigens can participate in the immune
process [28]. In our case, as the peptide construct bears a lipid
Fig. 5. Typical Biacore sensorgram obtained with di¡erent IgG con-
centrations of immune rabbit anti-MAP[VP1+VP3] that was immo-
bilised on the dextran matrix. Sensorgrams depicting real-time bind-
ing interaction between twofold dilutions of immune rabbit IgG
interacting at 10 Wl/min with MAP[VP1+VP3] covalently linked to
biosensor chip CM5. The antibody association phase is shown for
time 140^690 s and is followed immediately by the dissociation
phase 690^1300 s. Determination of dissociation rate constants Kd
(s31) were obtained from each curve as described in Section 2.
Table 4
Kinetic analysis of the sequential IgG antibody to HAV-MAP[VP1+VP3] peptide by three prede¢ned models (Langmuir, bivalent and heteroge-
neous ligand)
Weeks Langmuir Bivalent Heterogeneous ligand
Ka M2 Ka M2 Ka1 Ka2 M2
Rabbit 1
3 1.73U106 169 3.16U105 203 8.22U105 1.68U1011 118
6 8.27U105 55.9 4.20U104 47.2 1.04U104 1.42U109 22.4
9 6.38U106 36.5 6.84U103 31 6.45U106 6.49U106 37
12 8.83U105 142 1.42U104 144 3.26U106 3.25U106 144
Rabbit 2
3 1.77U106 105 2.07U105 4440 1.95U106 3.29U105 104
6 1.52U106 10.4 3.86U105 9.38 3.71U109 6.76U105 1.17
9 2.17U106 12.2 2.48U105 12.2 2.73U106 1.48U106 12.2
12 4.24U106 80.5 1.41U105 79.1 3.55U106 4.88U106 80.5
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tail of palmitic acid, and liposomes have been prepared by
mixing all components, it is logical to assume that the peptide
sequence is at least partly integrated between the lipid bilayers
of MLV liposomes, thus mimicking the natural presentation
of an epitope in the context of an in vivo antigenic situation.
Thus, it was gratifying to observe that in rabbit 2 immuni-
sation with MAP[VP1+VP3] in liposomes elicited speci¢c IgG
not only against MAP itself but also against the VP3 and VP1
antigens, which are contained in the MAP. However, in rabbit
1, no recognition was observed for the VP3 peptide. This
result could be explained by di¡erences in the VP3 conforma-
tion presented either in MAP^liposomes or mixed with
Freund’s adjuvant. Thus, the B cell epitope present in the
liposomal preparation appeared to be more accessible to anti-
bodies. Another possibility to explain di¡erences in mounting
an immune response is the timing of presentation of the pep-
tide by liposomes in comparison with Freund’s adjuvant, and
by activating di¡erent events in the antigen-presenting cells
[29].
Moreover, several factors could contribute to the procedure
adopted for serum analysis [30]. First, branched peptides bind
more readily to the microtitre wells than do monomeric pep-
tides. Second, multivalent binding between antibody and
branched peptide would result in a considerable increase in
stability, compared to simple monovalent binding of mono-
meric peptide. Third, to be immunoreactive monomeric pep-
tides have to both bind to the plastic well and remain avail-
able for binding to the antibody, whereas one or more arms of
a branched peptide could bind to the plastic and leave the
other(s) free to bind to the antibody. It is possible that in
binding to the plastic, physical constraints are imposed on a
monomeric peptide to prevent it from interacting freely with
the antibody.
Antibody a⁄nity constants have been measured by many
methods including competitive radioimmunoassay [31], com-
petitive ELISA [32], quantitation of eluted antibody [33], in-
direct ELISA [19], and more recently SPR technology [34].
These approaches have been applied to measure a⁄nity of
monoclonal antibodies but few studies have reported the avid-
ity of polyclonal antibodies that is the physiological immune
response after vaccination. We have used two di¡erent ap-
proaches, an indirect ELISA and a biosensor technology, to
estimate the avidity of antibody response to MAP peptides
inoculated with the Freund’s adjuvant protocol or entrapped
in liposomes.
In our studies, the experimental curves to calculate avidity
from the ELISA experiment do not ful¢l the theoretical curves
assumed in Beatty’s model, designed for monoclonal antibod-
ies. These discrepancies found in experimental results could be
attributed to the complexity of both antigen and antibody
analytes. The antigen is a complex peptide, exposing at least
three immunoreactive sites, VP1, VP3 and the conformational
MAP[VP1+VP3], and the antibody could be reactive with
mono- or bivalence.
Rabbit 1 recognised mainly the conformational epitopes of
MAP[VP1+VP3] (Fig. 3A) in all serum samples but in bleeds
corresponding to weeks 3 and 6 a reactivity against VP1 was
also detected. The measure of avidity, Ka, at these points
reaching 7.3U106 and 7.05U106 M31 respectively (Table 3),
could represent the summatory e¡ect of antibodies reacting
with both immunoepitopes.
However, in rabbit 2, the calculated avidity increased
throughout the study duration, as the reactivity against
MAP[VP1+VP3], VP1 and VP3 increased (Fig. 3B). Hence,
the calculated avidity may be an estimation of at least three
speci¢c antibodies. As shown in Table 3, the avidity constant
Ka ranges from 4.56U106 up to 2.90U107 M31.
The most problematic feature to calculate the avidity of
immune IgG by Biacore technology was to ¢nd a mathemat-
ical approach that conforms to the interaction model. Several
studies adopted a 1:1 solution phase a⁄nity model, whilst
others have used a 2:1 model or a model of complex inter-
actions.
The ligand MAP[VP1+VP3] contains more than one epi-
tope, as shown by indirect ELISA on immune sera that rec-
ognised the construct MAP[VP1+VP3], as well as each of the
linear parent peptides (Fig. 3). Furthermore, the IgG can in-
teract with the ligand by one or two Fab domains with each
of the exposed epitopes, thus becoming a complex model of
interaction. This is probably one of the reasons why none of
the simple analytical models of interactions ¢t with our data
(Table 4). However, comparisons of avidity can be established
by examining dissociation rate constants, which are inversely
proportional to avidity and independent of concentrations
under saturating conditions [21]. Thus, although di¡erent
measurement units were used, a good correlation was ob-
served between the 1/Kd value from SPR and the calculated
Ka from ELISA experiments (r=0.72 for rabbit 1 and r=0.99
for rabbit 2).
Both ELISA and SPR analysis indicated that liposomes
induced more avid antisera than immunisation with Freund’s
adjuvant in this particular formulation.
In conclusion, we have shown that MAP are able to mount
an antibody response either inoculated in Freund’s adjuvant
or entrapped in liposomes. The liposome preparations of the
palmitoyl derivative of MAP[VP1+VP3] induced a stronger
immune response, measured in terms of avidity and number
of epitopes recognised by the inoculated animal. In the light
of these results, the MAP constructs are suitable to be used as
immunogens mimicking the native protein, and the liposome
formulation of the lipophilic MAP o¡ers a valuable strategy
for the design of therapeutic vaccines.
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